Download PDF
Digestive Disease Interventions 2021; 05(02): 137-141
DOI: 10.1055/s-0041-1726867
Review Article

Radioembolization Outside of the Liver

Mari E. Tanaka 
1   Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
,
Eric Wehrenberg-Klee
2   Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Transarterial radioembolization (TARE) with yttrium-90 microspheres has emerged as an effective therapy for the treatment of both primary and metastatic hepatic lesions. It has been studied most extensively in hepatocellular carcinoma (HCC) and metastatic colorectal lesions (mCRC). The clinical success of TARE in HCC and mCRC has led to further investigation of expanding treatment to other malignancies involving the liver such as neuroendocrine carcinoma, uveal melanoma, and breast carcinoma, among others. Furthermore, interest in applications of TARE outside of the liver is emerging and small initial studies have been performed primarily in animal models to assess the effects of TARE on other organs such as the brain, stomach, spleen, kidney, and lungs. This review summarizes existing literature on the use of TARE outside of the liver.

Keywords

radioembolization - renal cell carcinoma - pulmonary metastatic disease - non-small cell lung cancer - spleen - stomach - glioblastoma


Publication History

Received: 30 November 2020

Accepted: 10 February 2021

Article published online:
15 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Sato KT, Lewandowski RJ, Mulcahy MF. et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology 2008; 247 (02) 507-515
    CrossrefPubMedGoogle Scholar
  • 2 Correa RJM, Louie AV, Staehler M. et al. Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney: a multicenter analysis from the IROCK. J Urol 2019; 201 (06) 1097-1104
    CrossrefPubMedGoogle Scholar
  • 3 Zimmermann A, Schubiger PA, Mettler D, Geiger L, Triller J, Rösler H. Renal pathology after arterial yttrium-90 microsphere administration in pigs. A model for superselective radioembolization therapy. Invest Radiol 1995; 30 (12) 716-723
    CrossrefPubMedGoogle Scholar
  • 4 de Silva S, Mackie S, Aslan P, Cade D, Delprado W. Histological comparison of kidney tissue following radioembolization with yttrium-90 resin microspheres and embolization with bland microspheres. Cardiovasc Intervent Radiol 2016; 39 (12) 1743-1749
    CrossrefPubMedGoogle Scholar
  • 5 Hamoui N, Gates VL, Gonzalez J, Lewandowski RJ, Salem R. Radioembolization of renal cell carcinoma using yttrium-90 microspheres. J Vasc Interv Radiol 2013; 24 (02) 298-300
    CrossrefPubMedGoogle Scholar
  • 6 Clark W, Aslan P, Patel M. et al. The RESIRT study: feasibility and dosimetry considerations of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC). J Vasc Interv Radiol 2017; 28 (02) S164
    CrossrefPubMedGoogle Scholar
  • 7 Kahn PC, Paul RE, Rheinlander HF. Selective bronchial arteriography and intra-arterial chemotherapy in carcinoma of the lung. J Thorac Cardiovasc Surg 1965; 50 (05) 640-645
    CrossrefPubMedGoogle Scholar
  • 8 Neyazaki T, Ikeda M, Seki Y, Egawa N, Suzuki C. Bronchial artery infusion therapy for lung cancer. Cancer 1969; 24 (05) 912-922
    CrossrefPubMedGoogle Scholar
  • 9 Soderberg Jr CH, Colbert MP, Leone LA. Bronchial artery infusion therapy of lung neoplasms with nitrogen mustard. Surgery 1964; 56: 897-904
    PubMedGoogle Scholar
  • 10 Osaki T, Hanagiri T, Nakanishi R, Yoshino I, Taga S, Yasumoto K. Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study. Chest 1999; 115 (05) 1424-1428
    CrossrefPubMedGoogle Scholar
  • 11 Nakanishi M, Umeda Y, Demura Y. et al. Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases. Lung Cancer 2007; 55 (02) 241-247
    CrossrefPubMedGoogle Scholar
  • 12 Ridge CA, Solomon SB. Percutaneous ablation of colorectal lung metastases. J Gastrointest Oncol 2015; 6 (06) 685-692
    PubMedGoogle Scholar
  • 13 Yan TD, King J, Sjarif A, Glenn D, Steinke K, Morris DL. Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol 2006; 13 (11) 1529-1537
    CrossrefPubMedGoogle Scholar
  • 14 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393 (10185): 2051-2058
    CrossrefPubMedGoogle Scholar
  • 15 De Ruysscher D, Faivre-Finn C, Nestle U. et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010; 28 (36) 5301-5310
    CrossrefPubMedGoogle Scholar
  • 16 Timmerman R, McGarry R, Yiannoutsos C. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24 (30) 4833-4839
    CrossrefPubMedGoogle Scholar
  • 17 Senthi S, Haasbeek CJA, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013; 106 (03) 276-282
    CrossrefPubMedGoogle Scholar
  • 18 Marks LB, Bentzen SM, Deasy JO. et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S70-S76
    CrossrefPubMedGoogle Scholar
  • 19 Ricke J, Großer O, Amthauer H. Y90-radioembolization of lung metastases via the bronchial artery: a report of 2 cases. Cardiovasc Intervent Radiol 2013; 36 (06) 1664-1669
    CrossrefPubMedGoogle Scholar
  • 20 Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning - Full Text View - ClinicalTrials.gov. Accessed November 23, 2020 at: https://clinicaltrials.gov/ct2/show/NCT04105283
    Google Scholar
  • 21 Tc99m Macroaggregated Albumin Bronchial Artery Study - Full Text View - ClinicalTrials.gov. Accessed November 23, 2020 at: https://clinicaltrials.gov/ct2/show/NCT04555564
    Google Scholar
  • 22 DRKS - Deutsches Register Klinischer Studien (German Clinical Trials Register). Accessed November 23, 2020 at: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021723
  • 23 Ariel IM, Padula G. Irradiation of the spleen by the intra-arterial administration of 90 yttrium microspheres in patients with malignant lymphoma. A preliminary report. Cancer 1973; 31 (01) 90-96
    CrossrefPubMedGoogle Scholar
  • 24 Muylle K, Nguyen J, de Wind A. et al. Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenomegaly. Cardiovasc Intervent Radiol 2013; 36 (04) 1155-1160
    CrossrefPubMedGoogle Scholar
  • 25 Becker CD, Rösler H, Biasiutti FD, Baer HU. Congestive hypersplenism: treatment by means of radioembolization of the spleen with Y-90. Radiology 1995; 195 (01) 183-186
    CrossrefPubMedGoogle Scholar
  • 26 Vujic I, Lauver JW. Severe complications from partial splenic embolization in patients with liver failure. Br J Radiol 1981; 54 (642) 492-495
    CrossrefPubMedGoogle Scholar
  • 27 Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia - Full Text View - ClinicalTrials.gov. Accessed January 22, 2021 at: https://clinicaltrials.gov/ct2/show/NCT03059030
    Google Scholar
  • 28 Weiss CR, Gunn AJ, Kim CY, Paxton BE, Kraitchman DL, Arepally A. Bariatric embolization of the gastric arteries for the treatment of obesity. J Vasc Interv Radiol 2015; 26 (05) 613-624
    CrossrefPubMedGoogle Scholar
  • 29 Paxton BE, Kim CY, Alley CL. et al. Bariatric embolization for suppression of the hunger hormone ghrelin in a porcine model. Radiology 2013; 266 (02) 471-479
    CrossrefPubMedGoogle Scholar
  • 30 Paxton BE, Alley CL, Crow JH. et al. Histopathologic and immunohistochemical sequelae of bariatric embolization in a porcine model. J Vasc Interv Radiol 2014; 25 (03) 455-461
    CrossrefPubMedGoogle Scholar
  • 31 Pasciak A, Bourgeois A, Arepally A. et al. Bariatric radiation therapy (BaRT): proof of concept in porcine model. J Vasc Interv Radiol 2016; 27 (03) S120
    CrossrefPubMedGoogle Scholar
  • 32 Pasciak AS, Bourgeois AC, Paxton BE. et al. Bariatric radioembolization: a pilot study on technical feasibility and safety in a porcine model. J Vasc Interv Radiol 2016; 27 (10) 1509-1517
    CrossrefPubMedGoogle Scholar
  • 33 Chang CH, Horton J, Schoenfeld D. et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52 (06) 997-1007
    CrossrefPubMedGoogle Scholar
  • 34 Shirazi HA, Grimm S, Raizer J, Mehta MP. Combined modality approaches in the management of adult glioblastoma. Front Oncol 2011; 1 (OCT): 36
    CrossrefPubMedGoogle Scholar
  • 35 Kleinberg L, Yoon G, Weingart JD. et al. Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence. Int J Radiat Oncol Biol Phys 2009; 75 (05) 1385-1391
    CrossrefPubMedGoogle Scholar
  • 36 Shah JL, Li G, Shaffer JL. et al. Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma. Neurosurgery 2018; 82 (01) 24-34
    CrossrefPubMedGoogle Scholar
  • 37 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 38 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013; 58 (06) 2188-2197
    CrossrefPubMedGoogle Scholar
  • 39 Rosenow UF, Findlay PA, Wright DC. The NCI-atlas of dose distributions for regular 125I brain implants. Radiother Oncol 1987; 10 (02) 127-139
    CrossrefPubMedGoogle Scholar
  • 40 Pasciak AS, Manupipatpong S, Hui FK. et al. Correction to: yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model. EJNMMI Res 2020; 10 (01) 104
    CrossrefPubMedGoogle Scholar